原发性肝癌研究当前面临的挑战

叶胜龙

doi:10.3969/j.issn.1001-5256.2015.06.001

原发性肝癌研究当前面临的挑战

DOI: 10.3969/j.issn.1001-5256.2015.06.001

叶胜龙

复旦大学肝癌研究所,复旦大学附属中山医院肝肿瘤内科

基金项目:

国家“十二五”科技重大专项课题(2012ZX10002-016)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 206
- HTML全文浏览量: 13
- PDF下载量: 795
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Current challenges to primary liver cancer research

Ye ShengLong

Liver Cancer Institute,Zhongshan Hospital,Fudan University

Research funding:

摘要

摘要: 原发性肝癌是常见恶性肿瘤,发病率和死亡率均呈升高趋势。近年来原发性肝癌临床研究不断取得长足进展,但仍面临严峻挑战。重点评述原发性肝癌相关的分子分型和干细胞基础研究、病理和临床诊断、临床分期、外科治疗、局部区域治疗、分子靶向治疗、系统化疗、门静脉癌栓治疗、抗病毒治疗、肝内胆管癌诊治及多模式综合治疗等方面当前的进展和研究难点,探讨进一步提高原发性肝癌临床研究水平的发展前景。
- 肝肿瘤 /
- 诊断 /
- 肿瘤治疗方案 /
- 述评
Abstract: Primary liver cancer is a common malignancy with increasing incidence and mortality. Remarkable progress has been made in the clinical research on liver cancer,but challenges to further improvement are still rigorous. This article reviews the progress and difficulties of primary liver cancer study from the following aspects: molecular classification and stem cell biology,pathological and clinical diagnosis,clinical staging,surgical treatment,loco- regional treatment,molecular targeted therapy,systemic chemotherapy,management of portal vein tumor thrombus,antiviral therapy,diagnosis and treatment of intrahepatic cholangiocarcinoma,and multimodality treatment. The future strategies to further improve primary liver cancer study are also investigated.
- liver neoplasms /
- diagnosis /
- antineoplastic protocols /
- editorial

HTML全文

参考文献(54)

[1]BRUIX J,GORES GJ,MAZZAFERRO V.Hepatocellular carcinoma:clinical frontiers and perspectives[J].Gut,2014,63(5):844-855.

[2]BRUIX J,HAN KH,GORES G,et al.Liver cancer:approaching a personalized care[J].J Hepatol,2015,62(1Suppl):s144-s156.

[3]YE SL.New advances in liver cancer research:a review of 2013[J].Chin J Hepatol,2014,22(1):2-4.(in Chinese)叶胜龙.2013年肝癌领域新进展[J].中华肝脏病杂志,2014,22(1):2-4.

[4]YE SL.Advances in research on hepatocellular carcinoma in 2014[J].Chin J Hepatol,2015,23(2):90-93.(in Chinese)叶胜龙.2014年肝细胞癌研究进展回顾[J].中华肝脏病杂志,2015,23(2):90-93.

[5]TORRE LA,BRAY F,SIEGEL RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.

[6]CHEN WQ,ZHENG RS,ZHANG SW,et al.Report of incidence and mortality in China cancer registries,2009[J].Chin J Cancer Res,2013,25(1):10-21.

[7]WEI KR,YU X,ZHENG RS,et al.Incidence and mortality of liver cancer in China,2010[J].Chin J Cancer,2014,33(8):388-394.

[8]HOU J,CAO XT.MicroRNAs in the management of hepatocellular carcinoma:new opportunities and challenges[J].Chin J Cancer Biother,2015,22(1):1-7.(in Chinese)侯晋,曹雪涛.MicroRNA与肝癌诊治:新的机遇和挑战[J].中国肿瘤生物治疗杂志,2015,22(1):1-7.

[9]OISHI N,YAMASHITA T,KANEKO.Molecular biology of liver cancer stem cells[J].Liver Cancer,2014,3(1):71-84.

[10]RAMAKRISHNA G,RASTOGI A,TREHANPATI N,et al.From cirrhosis to hepatocellular carcinoma:new molecular insights on inflammation and cellular senescence[J].Liver Cancer,2013,2(3-4):367-383.

[11] Chinese Society of Liver Cancer,Chinese Anti-Cancer Association,Liver Cancer Study Group,Chinese Society of Hepatology,Chinese Medical Association,Chinese Society of Pathology,Chinese AntiCancer Association,et al.Evidence-based practice guidelines for the standardized pathological diagnosis of primary liver cancer(2015 edition)[J].J Clin Hepatol,2015,31(6):833-839.(in Chinese)中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版)[J].临床肝胆病杂志,2015,31(6):833-839..

[12]European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2012,56(4):908-943.

[13]SONG P,GAO J,INAGAKI Y,et al.Biomarkers:evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China[J].Liver Cancer,2013,2(1):31-39.

[14]SHEN Q,FAN J,YANG XR,et al.Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma:a large scale,multicentre study[J].Lancet Oncol,2012,13(8):817-826.

[15]SAINI S,PRATT DS.Time to update radiological criteria for noninvasive diagnosis of hepatocellular carcinoma[J].Hepatol Int,2015,9(1):1-2.

[16]ICHUKAWA T,SANO K,MORISAKA H.Diagnosis of pathologically early HCC with EOB-MRI:experiences and current consensus[J].Liver Cancer,2014,3(2):97-107.

[17]TOYODA H,KUMADA T,TADA T,et al.Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC[J].Hepatol Int,2015,9(1):84-92.

[18]ZENG MS,YE HY,GUO L,et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients:a multicenter,open-label,phaseⅢstudy[J].Hepatobiliary Pancreat Dis Int,2013,12(6):607-616.

[19]SALVATORE V,BOLONDI L.Clinical impact of ultrasound-related techniques on the diagnosis of focal liver lesions[J].Liver Cancer,2012,1(3-4):238-246.

[20]YAU T,TANG VYF,YAO TJ,et al.Development of Hong Kong Liver Cancer Staging System with treatment stratification for patients with hepatocellular carcinoma[J].Gastroenrerology,2014,146(7):1691-1700.

[21]XU Q,KOBAYASHI S,YE X,et al.Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma:a meta-analysis of 16103 patients[J].Sci Rep,2014,4:7252.

[22]JOHNSON PJ,BERHANE S,KAGEBAYASHI C,et al.Assessment of liver function in patients with hepatocellular carcinoma:a new evidence-based approach-the ALBI Grade[J].J Clin Oncol,2015,33(6):550-558.

[23]AKAMATSU N,SUGAWARA Y,KOKUDO N.Living donor transplantation for patients with hepatocellular carcinoma[J].Liver Cancer,2014,3(2):108-118.

[24]LENCIONI R.Chemoembolization in patients with hepatocellular carcinoma[J].Liver Cancer,2012,1(1):41-50.

[25]FORNER A,GILABERT M,BRUIX J,et al.Treatment of intermediate-stage hepatocellular carcinoma[J].Nat Rev Clin Oncol,2014,11(9):525-535.

[26] RAOUL JL,GILABERT M,PIANA G.How to define transarterial chemoembolization failure or refractorness:a European perspective[J].Liver Cancer,2014,3(2):119-124.

[27]LIAPI E,GESCHWIND JF.Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma[J].Liver Cancer,2012,1(3-4):201-205.

[28]SHEN YC,LIN ZZ,HSU CH,et al.Clinical trials in hepatocellular carcinoma:an update[J].Liver Cancer,2013,2(3-4):345-364.

[29]PARK JW,AMARAPURKAR D,CHAO Y,et al.Consensus recommendations and review by an international expert panel on interventions in hepatocellular carcinoma(EPOIHCC)[J].Liver Int,2013,33(3):327-337.

[30]KIM HY,PARK JW.Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma:past,present,and future[J].Liver Cancer,2014,3(1):9-17.

[31]JOHNSON PJ,QIN S,PARK JW,et al.Brivanib versus sorafenib as first-line therapy in patients with unresectable,advanced hepatocellular carcinoma:results from the randomized phaseⅢBRISK-FL study[J].J Clin Oncol,2013,31(28):3517-3524.

[32]LLOVET JM,DECAENS T,RAOUL JL,et al.Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed:results from the randomized phaseⅢBRISK-PS study[J].J Clin Oncol,2013,31(28):3509-3516.

[33]CAINAP C,QIN S,HUANG WT,et al.Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma:results of a randomized phaseⅢtrial[J].J Clin Oncol,2015,33(2):172-179.

[34]ZHU AX,KUDO M,ASSENAT E,et al.Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib:the EVOLVE-1 randomized clinical trial[J].JAMA,2014,312(1):57-67.

[35]BRUIX J,TAK WY,GASBARRINI A,et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma:multicentre,open-label,phase II safety study[J].Eur J Cancer,2013,49(16):3412-3419.

[36]QIN SK,BAI YX,LIM HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol,2013,31(28):3501-3508.

[37]CHOK KH,CHEUNG TT,CHAN SC,et al.Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis[J].World J Surg,2014,38(2):490-496.

[38]YAMAMOTO Y,IKOMA H,MORIMURA R,et al.Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis[J].World J Gastroenterol,2015,21(1):246-253.

[39]XUE TC,XIE XY,ZHANG L,et al.Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis:a meta-analysis[J].BMC Gastroenterol,2013,13:60.

[40]LEE DS,SEONG J.Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis[J].Liver Cancer,2014,3(1):18-30.

[41]JEONG SW,JANG JY,SHIM KY,et al.Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis[J].Gut Liver,2013,7(6):696-703.

[42]ZHU K,CHEN J,LAI L,et al.Hepatocellular carcinoma with portal vein tumor thrombus:treatment with transarterial chemoembolization combined with sorafenib-a retrospective controlled study[J].Radiology,2014,272(1):284-293.

[43]PAN T,LI XS,XIE QK,et al.Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumor thrombus[J].Clin Oncol,2014,69(12):e553-561.

[44]Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to treat hepatitis B/C virus-related hepatocellular carcinoma[J].J Clin Hepatol,2014,30(5):390-395.(in Chinese)肝细胞癌抗病毒治疗专家组.HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志,2014,30(5):390-395.

[45]LAI CL,YUEN MF.Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy[J].Hepatology,2013,57(1):399-408.

[46] YIN JH,LI N,HAN YF,et al.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma:a two-stage longitudinal clinical study[J].J Clin Oncol,2013,31(29):3647-3655.

[47]HUANG G,LAI EC,LAU WY,et al.Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels[J].Ann Surg,2013,257(3):490-505.

[48]DAN JQ,ZHANG YJ,HUANG JT,et al.Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma:a retrospective study[J].Eur J Surg Oncol,2013,39(8):865-872.

[49]BRIDGEWATER J,GALLE PR,KHAN SA,et al.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J].J Hepatol,2014,60(6):1268-1289.

[50]WANG Y,LI J,XIA Y,et al.Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J].J Clin Oncol,2013,31(9):1188-1195.

[51]YE SL.Attach importance to multidisciplinary combination therapy for liver cancer[J].Chin J Hepatol,2013,21(5):321-323.(in Chinese)叶胜龙.重视原发性肝癌的多学科综合治疗[J].中华肝脏病杂志,2013,21(5):321-323.

[52]CHOI C,CHOI GH,KIM TH,et al.Multimodality management for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma[J].Liver Cancer,2014,3:405-416.

[53]Society of Liver Cancer,Guangdong Provincial Anti-Cancer Association.Establishment of multi-disciplinary team for comprehensive treatment of liver cancer-consensus of experts in Guangdong,China(1)[J].J Clin Hepatol,2014,30(11):1112-1115.(in Chinese)广东省抗癌协会肝癌专业委员会.肝癌多学科综合治疗团队建立-广东专家共识(1)[J].临床肝胆病杂志,2014,30(11):1112-1115.

[54]Society of Liver Cancer,Guangdong Provincial Anti-Cancer Association.Strategy and method of multi-disciplinary team for comprehensive treatment of liver cancer-consensus of experts in Guangdong,China(2)[J].J Clin Hepatol,2014,30(11):1116-1119.(in Chinese)广东省抗癌协会肝癌专业委员会.肝癌多学科联合治疗策略与方法-广东专家共识(2)[J].临床肝胆病杂志,2014,30(11):1116-1119.

施引文献

资源附件(0)

访问统计